Gliosarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Gliosarcoma – Pipeline Review, H1 2017’, provides an overview of the Gliosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gliosarcoma

The report reviews pipeline therapeutics for Gliosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gliosarcoma therapeutics and enlists all their major and minor projects

The report assesses Gliosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gliosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gliosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gliosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agenus Inc

Bristol-Myers Squibb Company

Celgene Corp

DelMar Pharmaceuticals Inc

ERC Belgium SA

Merck & Co Inc

Merrimack Pharmaceuticals Inc

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Nuo Therapeutics Inc

Progenics Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gliosarcoma - Overview 6

Gliosarcoma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Gliosarcoma - Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 17

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Gliosarcoma - Companies Involved in Therapeutics Development 24

Agenus Inc 24

Bristol-Myers Squibb Company 24

Celgene Corp 25

DelMar Pharmaceuticals Inc 25

ERC Belgium SA 26

Merck & Co Inc 26

Merrimack Pharmaceuticals Inc 27

Millennium Pharmaceuticals Inc 27

NewLink Genetics Corp 28

Northwest Biotherapeutics Inc 28

Novartis AG 29

Nuo Therapeutics Inc 29

Progenics Pharmaceuticals Inc 29

Tragara Pharmaceuticals Inc 30

Gliosarcoma - Drug Profiles 31

ALD-451 - Drug Profile 31

alisertib - Drug Profile 32

avadomide hydrochloride - Drug Profile 38

BMS-986016 - Drug Profile 40

dasatinib - Drug Profile 42

DCVax-L - Drug Profile 45

dianhydrogalactitol - Drug Profile 53

DNX-2401 - Drug Profile 68

ERC-1671 - Drug Profile 72

flucytosine + TBio-01 - Drug Profile 73

G-200 - Drug Profile 74

indoximod - Drug Profile 77

irinotecan hydrochloride - Drug Profile 83

irinotecan hydrochloride + TBio-02 - Drug Profile 95

lonafarnib - Drug Profile 97

M-032 - Drug Profile 99

marizomib - Drug Profile 100

p28 - Drug Profile 105

pazopanib hydrochloride - Drug Profile 107

pembrolizumab - Drug Profile 115

PSMA ADC - Drug Profile 167

RRX-001 - Drug Profile 171

sapanisertib - Drug Profile 173

SGT-53 - Drug Profile 176

TG-02 - Drug Profile 178

urelumab - Drug Profile 181

Gliosarcoma - Dormant Projects 184

Appendix 185

Methodology 185

Coverage 185

Secondary Research 185

Primary Research 185

Expert Panel Validation 185

Contact Us 185

Disclaimer 186

List of Tables

List of Tables

Number of Products under Development for Gliosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gliosarcoma – Pipeline by Agenus Inc, H1 2017

Gliosarcoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Gliosarcoma – Pipeline by Celgene Corp, H1 2017

Gliosarcoma – Pipeline by DelMar Pharmaceuticals Inc, H1 2017

Gliosarcoma – Pipeline by ERC Belgium SA, H1 2017

Gliosarcoma – Pipeline by Merck & Co Inc, H1 2017

Gliosarcoma – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Gliosarcoma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Gliosarcoma – Pipeline by NewLink Genetics Corp, H1 2017

Gliosarcoma – Pipeline by Northwest Biotherapeutics Inc, H1 2017

Gliosarcoma – Pipeline by Novartis AG, H1 2017

Gliosarcoma – Pipeline by Nuo Therapeutics Inc, H1 2017

Gliosarcoma – Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Gliosarcoma – Pipeline by Tragara Pharmaceuticals Inc, H1 2017

Gliosarcoma – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Gliosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports